http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2380731-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ccd9173f2aabd93562c916f9a2dbff4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2006-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9e4604763b54f2485cda6b246ac27d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8441ad73ad40d2c74b1beff2ec27a879 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63c6903123ec3249e68582c4ebb789d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b4961de35793e2b3d447c9a256aec26 |
| publicationDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2380731-T3 |
| titleOfInvention | Vaccines based on the use of VMA |
| abstract | A medicament that includes a kit of parts comprising the following components: a) a first component comprising one or more foreign proteins or a nucleic acid encoding the same or functional parts thereof, whose functional parts contain one or more substitutions, insertions and / or deletions when compared to wild-type protein although it has the same function as wild-type protein; and b) a second component comprising an Ankara Modified Vaccine Virus (VMA), which carries a nucleic acid sequence encoding a fusion protein comprising: - ubiquitin or a functional part thereof, whose functional part contains one or more substitutions, insertions and / or deletions when compared to wild-type protein although it has the same function as wild-type protein; and - one or more foreign proteins, that is, one or more proteins that are not naturally present as a part of the VMA or functional parts thereof, whose functional part comprises one or more substitutions, insertions and / or deletions when it compares with the wild-type protein although it has the same function as the wild-type protein; wherein the one or more foreign proteins are the same in a) and b), and in which the first and second components further comprise a pharmaceutically acceptable carrier. |
| priorityDate | 2005-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 156.